Loading...

Europlasma

DB:1EZ
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1EZ
DB
€12M
Market Cap
  1. Home
  2. DE
  3. Commercial Services
Company description

Europlasma S.A., together with its subsidiaries, engages in plasma solutions, renewable energies, and asbestos waste treatment activities in France. The last earnings update was 176 days ago. More info.


Add to Portfolio Compare Print
1EZ Share Price and Events
7 Day Returns
0%
DB:1EZ
0.1%
DE Commercial Services
0.8%
DE Market
1 Year Returns
-
DB:1EZ
-6.3%
DE Commercial Services
-4.5%
DE Market
1EZ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Europlasma (1EZ) 0% 0% - - -93.8% -
DE Commercial Services 0.1% 3.3% 10.1% -6.3% 3.5% -41.2%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • No trading data on 1EZ.
  • No trading data on 1EZ.
Price Volatility
1EZ
Industry
5yr Volatility vs Market
Related Companies

1EZ Value

 Is Europlasma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Europlasma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Europlasma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Europlasma. This is due to cash flow or dividend data being unavailable. The share price is €0.044.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Europlasma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Europlasma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1EZ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.13
ENXTPA:ALEUP Share Price ** ENXTPA (2019-03-08) in EUR €0.04
Europe Commercial Services Industry PE Ratio Median Figure of 105 Publicly-Listed Commercial Services Companies 17.06x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Europlasma.

DB:1EZ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALEUP Share Price ÷ EPS (both in EUR)

= 0.04 ÷ -0.13

-0.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Europlasma is loss making, we can't compare its value to the Europe Commercial Services industry average.
  • Europlasma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Europlasma's expected growth come at a high price?
Raw Data
DB:1EZ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.31x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Commercial Services Industry PEG Ratio Median Figure of 53 Publicly-Listed Commercial Services Companies 1.4x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Europlasma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Europlasma's assets?
Raw Data
DB:1EZ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €-0.05
ENXTPA:ALEUP Share Price * ENXTPA (2019-03-08) in EUR €0.04
Germany Commercial Services Industry PB Ratio Median Figure of 8 Publicly-Listed Commercial Services Companies 2.03x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:1EZ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALEUP Share Price ÷ Book Value per Share (both in EUR)

= 0.04 ÷ -0.05

-0.82x

* Primary Listing of Europlasma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Europlasma has negative assets, we can't compare the value of its assets to the DE Commercial Services industry average.

Next steps:

  1. Take a look at our analysis of 1EZ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Europlasma's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Commercial Services industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Europlasma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. Europlasma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1EZ Future Performance

 How is Europlasma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Europlasma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
31.4%
Expected Commercial Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Europlasma expected to grow at an attractive rate?
  • Unable to compare Europlasma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Europlasma's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Europlasma's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:1EZ Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 31.4%
Germany Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 3.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1EZ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1EZ Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:1EZ Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 18 -12 -21
2018-03-31 17 -12 -22
2017-12-31 16 -11 -22
2017-09-30 13 -10 -21
2017-06-30 10 -10 -19
2017-03-31 11 -9 -18
2016-12-31 12 -8 -17
2016-09-30 13 -8 -16
2016-06-30 14 -8 -15
2016-03-31 15 -10 -16
2015-12-31 16 -12 -16
2015-09-30 15 -14 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Europlasma is high growth as no earnings estimate data is available.
  • Unable to determine if Europlasma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1EZ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Europlasma Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1EZ Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:1EZ Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.13
2018-03-31 -0.15
2017-12-31 -0.16
2017-09-30 -0.17
2017-06-30 -0.19
2017-03-31 -0.20
2016-12-31 -0.23
2016-09-30 -0.22
2016-06-30 -0.22
2016-03-31 -0.23
2015-12-31 -0.23
2015-09-30 -0.35

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Europlasma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 1EZ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Europlasma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Commercial Services companies here
  3. Europlasma's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Europlasma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Europlasma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1EZ Past Performance

  How has Europlasma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Europlasma's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Europlasma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Europlasma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Europlasma's 1-year growth to the Europe Commercial Services industry average as it is not currently profitable.
Earnings and Revenue History
Europlasma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Europlasma Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1EZ Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 17.54 -21.20 15.28
2018-03-31 16.56 -21.52 14.88
2017-12-31 15.58 -21.83 14.47
2017-09-30 12.89 -20.64 14.28
2017-06-30 10.21 -19.45 14.08
2017-03-31 10.94 -18.40 14.21
2016-12-31 11.66 -17.35 14.34
2016-09-30 13.07 -16.39 14.71
2016-06-30 14.48 -15.44 15.09
2016-03-31 15.32 -15.80 14.95
2015-12-31 16.15 -16.16 14.81
2015-09-30 14.62 -21.97 13.55
2015-06-30 13.08 -27.78 12.28
2015-03-31 11.82 -26.89 11.95
2014-12-31 10.55 -25.99 11.63
2014-09-30 12.70 -19.90 12.16
2014-06-30 14.86 -13.81 12.69
2014-03-31 15.44 -11.49 11.84
2013-12-31 16.03 -9.17 10.99
2013-09-30 19.03 -14.97 13.77
2013-06-30 22.04 -20.77 16.56
2013-03-31 32.03 -20.83 20.25
2012-12-31 42.03 -20.89 23.95
2012-09-30 52.16 -11.66 23.96
2012-06-30 62.29 -2.43 23.97

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Europlasma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Europlasma has efficiently used its assets last year compared to the Europe Commercial Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Europlasma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Europlasma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Europlasma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1EZ Health

 How is Europlasma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Europlasma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Europlasma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Europlasma's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Europlasma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Europlasma Company Filings, last reported 9 months ago.

DB:1EZ Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 4.14 31.89 3.92
2018-03-31 4.14 31.89 3.92
2017-12-31 -15.19 18.84 5.77
2017-09-30 -15.19 18.84 5.77
2017-06-30 -7.25 13.06 3.08
2017-03-31 -7.25 13.06 3.08
2016-12-31 -3.55 13.40 4.88
2016-09-30 -3.55 13.40 4.88
2016-06-30 -5.18 14.97 4.84
2016-03-31 -5.18 14.97 4.84
2015-12-31 2.60 12.62 7.54
2015-09-30 2.60 12.62 7.54
2015-06-30 7.42 8.68 7.26
2015-03-31 7.42 8.68 7.26
2014-12-31 16.92 9.34 14.25
2014-09-30 16.92 9.34 14.25
2014-06-30 -0.92 19.58 1.96
2014-03-31 -0.92 19.58 1.96
2013-12-31 3.12 17.75 2.67
2013-09-30 3.12 17.75 2.67
2013-06-30 8.70 13.25 1.36
2013-03-31 8.70 13.25 1.36
2012-12-31 15.94 24.09 4.89
2012-09-30 15.94 24.09 4.89
2012-06-30 33.47 19.32 8.30
  • Europlasma's level of debt (769.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (153.8% vs 769.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Europlasma has less than a year of cash runway based on current free cash flow.
  • Europlasma has less than a year of cash runway if free cash flow continues to reduce at historical rates of -1.7% each year.
X
Financial health checks
We assess Europlasma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Europlasma has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1EZ Dividends

 What is Europlasma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Europlasma dividends.
If you bought €2,000 of Europlasma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Europlasma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Europlasma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1EZ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 3.3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1EZ Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Europlasma has not reported any payouts.
  • Unable to verify if Europlasma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Europlasma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Europlasma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Europlasma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Europlasma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Europlasma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1EZ Management

 What is the CEO of Europlasma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jean-Eric Petit
COMPENSATION €538,000
AGE 55
CEO Bio

Mr. Jean-Eric Petit has been the Managing Director at Europlasma Société Anonyme since January 6, 2014 and serves as its Chief Executive Officer. Mr. Petit was a Sector Partner of 3i Group Plc since 2000. He served as an Industrial Advisor. Mr. Petitin was based at Paris office and was responsible for aerospace and environment investment opportunities. Deals that he had been closely involved in, include SR Technics, Aviapartner, Pilatus, Global Energy Services, Konarka and Keolis. Mr. Petit has experience in several manufacturing and services industries. He started his career at Chromalloy as a Sales Director, before joining Intertechnique as a Commercial Director. Mr. Petit then became the Chief Executive Officer of CNIM UK, successfully turning its subsidiary, Martin Engineering Systems Ltd., into the premier energy-from-waste company in the UK. He was a director of the Energy-from-Waste Association. He has kept close ties with various UK-based renewable energy organisations and with GIFAS (the French Aerospace Association). He has been a Director of Europlasma Société Anonyme since January 24, 2014. Mr. Petit holds a degree in Engineering from the ESTP (Ecole Supérieure des Travaux Publics) and an International M.B.A. from CESMA (Lyons).

CEO Compensation
  • Jean-Eric's compensation has been consistent with company performance over the past year.
  • Jean-Eric's remuneration is higher than average for companies of similar size in Germany.
Management Team

Jean-Eric Petit

TITLE
CEO, MD & Director
COMPENSATION
€538K
AGE
55

Pierre Bellmann

TITLE
Chief Operating Officer of Europe Environment Group and Managing Director of Europe Environnement
Board of Directors Tenure

Average tenure of the Europlasma board of directors in years:

7
Average Tenure
  • The tenure for the Europlasma board of directors is about average.
Board of Directors

Pierre Catlin

TITLE
Non-Executive Chairman
COMPENSATION
€84K
TENURE
8.7 yrs

Jean-Eric Petit

TITLE
CEO, MD & Director
COMPENSATION
€538K
AGE
55
TENURE
5.3 yrs

Kim Lee

TITLE
Independent Director
COMPENSATION
€20K
TENURE
10.6 yrs

Yann Le Doré

TITLE
Independent Director
COMPENSATION
€20K
TENURE
3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Europlasma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Europlasma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1EZ News

Simply Wall St News

1EZ Company Info

Description

Europlasma S.A., together with its subsidiaries, engages in plasma solutions, renewable energies, and asbestos waste treatment activities in France. The company provides plasma solutions for gas and hazardous wastes; and produces electricity from waste and biomass gasification. It also offers destruction and valorization of asbestos waste. Europlasma S.A. was founded in 1992 and is based in Pessac, France.

Details
Name: Europlasma S.A.
1EZ
Exchange: DB
Founded: 1992
€11,762,742
284,812,178
Website: http://www.europlasma.com
Address: Europlasma S.A.
3-5 Allée des lumières,
Cité de la Photonique,
Pessac,
Aquitaine, 33600,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALEUP Ordinary Shares Euronext Paris FR EUR 28. Sep 2001
OTCPK ERPL.F Ordinary Shares Pink Sheets LLC US USD 28. Sep 2001
DB 1EZ Ordinary Shares Deutsche Boerse AG DE EUR 28. Sep 2001
BST 1EZ Ordinary Shares Boerse-Stuttgart DE EUR 28. Sep 2001
LSE 0W8R Ordinary Shares London Stock Exchange GB EUR 28. Sep 2001
Number of employees
Current staff
Staff numbers
116
Europlasma employees.
Industry
Environmental and Facilities Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:33
End of day share price update: 2019/03/08 00:00
Last estimates confirmation: 2018/04/17
Last earnings filing: 2018/10/31
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.